<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03379259</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-900-101</org_study_id>
    <nct_id>NCT03379259</nct_id>
  </id_info>
  <brief_title>Study of BGB-A333 Alone and in Combination With BGB-A317 in Advanced Solid Tumors</brief_title>
  <official_title>Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death
      1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1
      (PD-1). BGB-A317 is a humanized, IgG4-variant monoclonal antibody against PD-1. This study
      tests the safety and anti-tumor effect of BGB-A333 alone and in combination with BGB-A317 in
      patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: the number of Adverse Events</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: The number of Serious Adverse Events</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: the Maximum Tolerated Dose (MTD), if any, and Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall Response Rate (ORR) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall Response Rate (ORR) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Duration of Response (DOR) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Disease Control Rate (DCR) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of Response (DOR) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression-free Survival (PFS) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Disease Control Rate (DCR) determined by investigators based on RECIST Version 1.1</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: the number of Adverse Events</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: the number of Serious Adverse Events</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and Phase 2: Plasma concentrations of BGB-A333</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1B and Phase 2B: Plasma concentrations of BGB-A317</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and Phase 2: the percentage of patients who develop detectable anti-drug antibodies</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1A: BGB-A333 monotherapy dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2A: BGB-A333 monotherapy dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1B: BGB-A333 and BGB-A317 dose confirmation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2B: BGB-A333 and BGB-A317 dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A333</intervention_name>
    <description>Anti-PD-L1 antibody</description>
    <arm_group_label>Phase 1A: BGB-A333 monotherapy dose escalation</arm_group_label>
    <arm_group_label>Phase 2A: BGB-A333 monotherapy dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A333 and BGB-A317</intervention_name>
    <description>Anti-PD-L1 and anti-PD-1 antibodies</description>
    <arm_group_label>Phase 1B: BGB-A333 and BGB-A317 dose confirmation</arm_group_label>
    <arm_group_label>Phase 2B: BGB-A333 and BGB-A317 dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed advanced or metastatic disease
             (unresectable) that is resistant to standard therapy or for which treatment is not
             available, not tolerated or refused

          2. Has Eastern Cooperative Oncology Group (ECOG) Performance Status â‰¤1

          3. Has adequate organ function

        Exclusion Criteria:

          1. Active brain or leptomeningeal metastasis.

          2. Active autoimmune diseases or history of autoimmune diseases that may relapse.

          3. With severe chronic or active infections requiring systemic antibacterial, antifungal
             or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is
             permitted for patients with hepatocellular carcinoma)

          4. Concurrent participation in another therapeutic clinical trial.

          5. Received prior therapies targeting PD-1 or PD-L1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dewan Zeng</last_name>
    <phone>650-773-8208</phone>
    <email>dewan.zeng@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

